Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors
Bewersdorf JP, Shallis RM, Derkach A, Goldberg AD, Stein A, Stein EM, Marcucci G, Zeidan AM, Shimony S, DeAngelo DJ, Stone RM, Aldoss I, Ball BJ, Stahl M. Venetoclax-based salvage therapy in patients with relapsed/refractory acute myeloid leukemia previously treated with FLT3 or IDH1/2 inhibitors. Leukemia & Lymphoma 2022, 64: 188-196. PMID: 36287540, PMCID: PMC9905301, DOI: 10.1080/10428194.2022.2136952.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaSalvage therapyIDH1/2 inhibitorsIDH2 inhibitorsMyeloid leukemiaResponse rateRefractory acute myeloid leukemiaEffective salvage therapyLow-dose cytarabineMedian overall survivalRetrospective cohort studyOverall response rateLow response rateCohort studyOverall survivalAML patientsTreatment optionsFLT3 inhibitorsITD mutationPatientsTherapyFLT3Little dataVenetoclaxInhibitorsHealth-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML).
Dinardo C, Montesinos P, Schuh A, Papayannidis C, Vyas P, Wei A, Zeidan A, Chen C, Lord-Bessen J, Yu P, Shi L, Guo S, Bluemmert I, Yu X, Hasan M, Regueira P, De Botton S. Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML). Journal Of Clinical Oncology 2022, 40: 7032-7032. DOI: 10.1200/jco.2022.40.16_suppl.7032.Peer-Reviewed Original ResearchConventional care regimensEvent-free survivalEQ-5DR AMLCare regimensGlobal health status/QoLRefractory acute myeloid leukemiaVisual analog scale scoreWorse event-free survivalEORTC QLQ-C30 questionnaireSecondary trial endpointsComplete remission rateAnalog scale scoreHealth-related qualityMean HRQoL scoresQLQ-C30 questionnaireClinical efficacy measuresUtility indexMean EQ-5DAcute myeloid leukemiaQLQ-C30 domainsYears of ageLow response rateHRQOL endpointsOlder pts